Target identification for CNS diseases by transcriptional profiling

Area of Science:

• Neuroscience
• Genomics
• Pharmacology

Background:

• Gene expression profiling in neuropsychiatric and neurodegenerative disorders offers novel central nervous system (CNS) drug discovery targets.
• Replicated gene and pathway targets from human postmortem brain, animal models, and cell culture studies are summarized.

Purpose of the Study:

• To review and identify replicated gene and pathway targets across various neurological and psychiatric conditions.
• To highlight potential therapeutic strategies based on gene expression analysis for CNS disorders and aging.

Main Methods:

• Comprehensive review of gene expression profiling studies.
• Analysis of data from human postmortem brain tissue, animal models, and cell culture experiments.
• Identification of commonly implicated genes and pathways across different CNS disorders.

Main Results:

• Alzheimer's disease and cognitive decline targets include neurotrophin receptors, fibroblast growth factor (FGF) system, synapse markers, glutamate receptors (GluRs), and dopamine (DA) D2 receptors.
• Parkinson's disease candidates involve the ubiquitin-proteosome system, reactive oxygen species scavengers, brain-derived neurotrophic factor (BDNF), and associated signaling pathways.
• Schizophrenia shows decreased GABA function genes, BDNF/TrkB, 14-3-3 proteins, and metabolic genes; bipolar disorder implicates 14-3-3 proteins; depression reveals altered glutamate, neurotrophic, and MAP kinase pathways.

Conclusions:

• Gene expression analysis provides a robust framework for identifying CNS drug targets for neurodegenerative and psychiatric disorders.
• Restoring antioxidant, DNA repair, and synaptic functions, including dopamine signaling, may mitigate age-related cognitive decline.
• Targeting neurotrophic factors, growth factors, and specific signaling pathways presents promising therapeutic avenues for various brain disorders.